Neurobiological Technologies Overview

  • Founded
  • 1987
  • Status
  • Public
  • Employees
  • 6
  • Stock Symbol
  • NTII
Stock Symbol

Neurobiological Technologies General Information


Neurobiological Technologies Inc is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Other Industries
Other Healthcare Services
Stock Exchange
Primary Office
  • 2010 Crow Canyon Place
  • Suite 100
  • San Ramon, CA 94583
  • United States
+1 (925) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurobiological Technologies Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS

Neurobiological Technologies Financials Summary

In Thousands,
TTM 30-Sep-2009 FY 2009 30-Jun-2009 FY 2008 30-Jun-2008 FY 2007 30-Jun-2007
EV (2,005) (5,624) 9,829 53,478
Revenue 28,811 26,350 14,760 17,673
EBITDA 8,721 2,507 (13,898)
Net Income 11,290 3,123 (16,322) (14,128)
Total Assets 29,782 24,660 43,187 10,921
Total Debt 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Neurobiological Technologies Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Neurobiological Technologies‘s full profile, request access.

Request a free trial

Neurobiological Technologies Patents

Neurobiological Technologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20040224006-A1 Defibrinogenating agent, e.g., ancrod, urokinase, streptokinase, phenobarbital or valproic acid; or a fibrinolytic agent, e.g., advance-generation fibrates, e.g., fenofibrate, a tissue-plasminogen activator that may be recombinant, or a fibrinolytic derivative of recombinant tissue-plasminogen activator Abandoned 21-Apr-2003 0000000000 0
AU-6104196-A Novel n-substituted-2-amino-3',4'-methylene-dioxypropiopheno nes Abandoned 06-Jun-1995 0000000000
CA-2175457-A1 Treatment for rheumatoid arthritis Abandoned 02-Nov-1993 00000000000
AU-8131694-A Treatment for rheumatoid arthritis Abandoned 02-Nov-1993 00000000000
EP-0726780-A1 Treatment for rheumatoid arthritis Withdrawn 02-Nov-1993 A61K38/2228
To view Neurobiological Technologies’s complete patent history, request access »

Neurobiological Technologies Executive Team (4)

Name Title Board Seat Contact Info
William Fletcher Chief Executive Officer & Board Member
Matthew Loar Chief Financial Officer, Finance & Board Member
John Stuppin Co-Founder
You’re viewing 3 of 4 executive team members. Get the full list »

Neurobiological Technologies Board Members (6)

Name Representing Role Since
0000000 00000 Self Chairman & Board Member 000 0000
0000000 000000 Neurobiological Technologies Board Member 000 0000
0000 0000000 Neurobiological Technologies Co-Founder 000 0000
0000000 0000 Neurobiological Technologies Chief Financial Officer, Finance & Board Member 000 0000
00000000 00000 Neurobiological Technologies Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Neurobiological Technologies Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial